Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients

Cancer Treatment Reviews

Volumn 37, Issue 8, 2011, Pages 643-654

  Vajda, Alice ^a   Marignol, Laure ^a   Foley, Ruth ^a   Lynch, Thomas H ^a   Lawler, Mark ^b   Hollywood, Donal ^c  

^a ST JAMES S HOSPITAL   (Ireland)

^b Dublin Molecular Medicine Centre   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

GDEPT; Gene directed enzyme prodrug therapy; Prostate cancer; Radiation therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOSINE DEAMINASE; DNA POLYMERASE; DYNAMIN II; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HERPESVIRUS VECTOR; LIPOSOME; NITROREDUCTASE; OSTEOCALCIN; PARVOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; RETROVIRUS VECTOR; SITIMAGENE CERADENOVEC; THYMIDINE TRIPHOSPHATE; TRETAZICAR; VALACICLOVIR; VALGANCICLOVIR;

ADENOVIRUS 5; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; BLADDER DISEASE; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER PATIENT; CANCER THERAPY; CELL DEATH; CELL KILLING; CHEMICAL MODIFICATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; DIGESTIVE SYSTEM INJURY; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENITAL INJURY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LIVER TOXICITY; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS CANCER; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN EXPRESSION; PSAMMOMA BODY; RADIOSENSITIVITY; REVIEW; RNA PROCESSING; SALVAGE THERAPY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; TRANSGENE; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VIRAL GENE DELIVERY SYSTEM;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ENZYME THERAPY; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; PRODRUGS; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY;

EID: 80054081416     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.03.003     Document Type: Review

References (136)

1. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 17:1598-1604.
2. Freytag S.O., Stricker H., Pegg J., et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003, 21:7497-7506.
3. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008, 2:191-201.
4. MacRae E.J., Giannoudis A., Ryan R., et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006, 5:470-494.
5. Greco O., Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001, 1:22-36.
6. Anello R., Cohen S., Atkinson G., Hall S.J. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation. J Urol 2000, 6:2173-2177.
7. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007, 1:4-41.
8. Huber B.E., Austin E.A., Richards C.A., Davis S.T., Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994, 17:8302-8306.
9. Kuriyama S., Masui K., Sakamoto T., et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res 1998, 5A:3399-3406.
10. Bentires-Alj M., Hellin A.C., Lechanteur C., et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther 2000, 1:20-26.
11. Ichikawa T., Tamiya T., Adachi Y., et al. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther 2000, 1:74-82.
12. Elion G.B., Furman P.A., Fyfe J.A., et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977, 12:5716-5720.
13. Miller W.H., Miller R.L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980, 15:7204-7207.
14. Elion G.B. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 1983, 9-17.
15. Mar E.C., Chiou J.F., Cheng Y.C., Huang E.S. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-methyluracil, -5-iodocytosine, and -5-methylcytosine. J Virol 1985, 3:846-851.
16. Caruso M., Panis Y., Gagandeep S., et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993, 15:7024-7028.
17. Freeman S.M., Abboud C.N., Whartenby K.A., et al. The " bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993, 21:5274-5283.
18. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000, 15:3989-3999.
19. Gagandeep S., Brew R., Green B., et al. Prodrug-activated gene therapy: involvement of an immunological component in the " bystander effect" Cancer Gene Ther 1996, 2:83-88.
20. Vile R.G., Castleden S., Marshall J., et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997, 2:267-274.
21. Tasciotti E., Giacca M. Fusion of the human immunodeficiency virus type 1 tat protein transduction domain to thymidine kinase increases bystander effect and induces enhanced tumor killing in vivo. Hum Gene Ther 2005, 12:1389-1403.
22. Patel P., Young J.G., Mautner V., et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 2009, 7:1292-1299.
23. Bridgewater J.A., Knox R.J., Pitts J.D., Collins M.K., Springer C.J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 1997, 6:709-717.
24. McErlane V., Yakkundi A., McCarthy H.O., et al. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 2005, 7:851-859.
25. Zhou D., Lu Y., Steiner M.S., Dalton J.T. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrob Agents Chemother 2000, 10:2659-2663.
26. Parker W.B., Allan P.W., Shaddix S.C., et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998, 10:1673-1681.
27. Russell P.J., Khatri A. Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opin Investig Drugs 2006, 8:947-961.
28. Martiniello-Wilks R., Garcia-Aragon J., Daja M.M., et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 1998, 11:1617-1626.
29. Wang X.Y., Martiniello-Wilks R., Shaw J.M., et al. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther 2004, 21:1559-1567.
30. Martiniello-Wilks R., Dane A., Voeks D.J., et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004, 1:43-54.
31. Harrington K.J., Spitzweg C., Bateman A.R., Morris J.C., Vile R.G. Gene therapy for prostate cancer: current status and future prospects. J Urol 2001, 4:1220-1233.
32. Ficazzola M.A., Taneja S.S. Prospects for gene therapy in human prostate cancer. Mol Med Today 1998, 11:494-504.
33. Lu Y., Carraher J., Zhang Y., et al. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 1999, 1:64-72.
34. DeWeese T.L., van der Poel H., Li S., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 20:7464-7472.
35. Barton K.N., Freytag S.O., Nurushev T., et al. A model for optimizing adenoviral delivery in human cancer gene therapy trials. Hum Gene Ther 2007, 6:562-572.
36. Dorer D.E., Nettelbeck D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009, 7-8:554-571.
37. Wu L., Matherly J., Smallwood A., et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther 2001, 18:1416-1426.
38. Gotoh A., Ko S.C., Shirakawa T., et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998, 1:220-229.
39. Watt F., Martorana A., Brookes D.E., et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001, 3:243-254.
40. Uchida A., O'Keefe D.S., Bacich D.J., Molloy P.L., Heston W.D. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001, 2(Suppl. 1):132-139.
41. Greenberg N.M., DeMayo F.J., Sheppard P.C., et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994, 2:230-239.
42. Kubo H., Gardner T.A., Wada Y., et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003, 3:227-241.
43. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 6:437-447.
44. Shibata T., Akiyama N., Noda M., Sasai K., Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998, 4:913-916.
45. Liu J., Harada H., Ogura M., Shibata T., Hiraoka M. Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts. Br J Cancer 2007, 12:1871-1878.
46. Fitzgerald T.J., Wang T., Goel H.L., et al. Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Rev Anticancer Ther 2008, 6:967-974.
47. Teh B.S., Aguilar-Cordova E., Vlachaki M.T., et al. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist 2002, 5:458-466.
48. Mangar S.A., Huddart R.A., Parker C.C., et al. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 2005, 6:908-921.
49. Herman J.R., Adler H.L., Aguilar-Cordova E., et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999, 7:1239-1249.
50. Lawrence T.S., Tepper J.E., Blackstock A.W. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 1997, 4:260-266.
51. Goblirsch M., Zwolak P., Ramnaraine M.L., et al. Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin Cancer Res 2006, 10:3168-3176.
52. Chhikara M., Huang H., Vlachaki M.T., et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 2001, 4:536-542.
53. Egami T., Ohuchida K., Mizumoto K., et al. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin Cancer Res 2008, 6:1859-1867.
54. Qian J., Yang J., Dragovic A.F., et al. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Res 2005, 13:5493-5497.
55. Zeng M., Cerniglia G.J., Eck S.L., Stevens C.W. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther 1997, 9:1025-1032.
56. Zhang M., Li S., Li J., Ensminger W.D., Lawrence T.S. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther 2003, 1:21-28.
57. Scherr D., Swindle P.W., Scardino P.T. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003, 2(Suppl):14-24.
58. Suzuki H., Kamiya N., Imamoto T., et al. Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 2008, 5:401-410.
59. Rukstalis D.B. Treatment options after failure of radiation therapy - a review. Rev Urol 2002, S12-S17.
60. Roberts W.B., Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol 2009, 3:268-274.
61. Bianco F.J., Scardino P.T., Stephenson A.J., et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005, 2:448-453.
62. Amling C.L., Lerner S.E., Martin S.K., et al. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999, 3:857-62. [discussion 62-3].
63. Ward J.F., Sebo T.J., Blute M.L., Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005, 4:1156-1160.
64. Bales G.T., Williams M.J., Sinner M., Thisted R.A., Chodak G.W. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 1995, 5:676-680.
65. Kimura M., Mouraviev V., Tsivian M., et al. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 2010, 105:191-201.
66. Ghafar M.A., Johnson C.W., De La Taille A., et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001, 4:1333-1337. [discussion 7-8].
67. Boukaram C., Hannoun-Levi J.M. Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treat Rev 2010, 36:91-100.
68. Nguyen P.L., Chen M.H., D'Amico A.V., et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007, 7:1485-1492.
69. Wong W.W., Buskirk S.J., Schild S.E., Prussak K.A., Davis B.J. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006, 5:2020-2024.
70. Zacharakis E., Ahmed H.U., Ishaq A., et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 2008, 7:786-792.
71. Murat F.J., Poissonnier L., Rabilloud M., et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 2009, 3:640-647.
72. Gelet A., Chapelon J.Y., Poissonnier L., et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004, 4:625-629.
73. Miles B.J., Shalev M., Aguilar-Cordova E., et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001, 16:1955-1967.
74. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994, 2:670-678.
75. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002, 23:4567-4573.
76. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997, 5:941-947.
77. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997, 3:213-221.
78. Rodriguez R., Schuur E.R., Lim H.Y., et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997, 13:2559-2563.
79. Freytag S.O., Stricker H., Movsas B., Kim J.H. Prostate cancer gene therapy clinical trials. Mol Ther 2007, 6:1042-1052.
80. Freytag S.O., Khil M., Stricker H., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002, 17:4968-4976.
81. Freytag S.O., Stricker H., Peabody J., et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007, 3:636-642.
82. Consalvo M., Mullen C.A., Modesti A., et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995, 10:5302-5312.
83. Teh B.S., Aguilar-Cordova E., Kernen K., et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report. Int J Radiat Oncol Biol Phys 2001, 3:605-613.
84. Teh B.S., Ayala G., Aguilar L., et al. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 2004, 5:1520-1529.
85. Freytag S.O., Movsas B., Aref I., et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007, 5:1016-1023.
86. Lu M, Freytag SO, Stricker H et al. Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP trial). Contemp Clin Trials; 2011. doi:10.1016/j.cct.2011.01.013. doi:10.1016/j.cct.2011.01.013.
87. Bubendorf L., Schopfer A., Wagner U., et al. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol 2000, 5:578-583.
88. Roudier M.P., True L.D., Vessella R.L., Higano C.S. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol 2004, 3:321-323.
89. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 15:1502-1512.
90. Desbois C., Hogue D.A., Karsenty G. The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J Biol Chem 1994, 2:1183-1190.
91. Matsubara S., Wada Y., Gardner T.A., et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001, 16:6012-6019.
92. Shirakawa T., Terao S., Hinata N., et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 2007, 12:1225-1232.
93. Philipson L., Lonberg-Holm K., Pettersson U. Virus-receptor interaction in an adenovirus system. J Virol 1968, 10:1064-1075.
94. Pandha H.S., Stockwin L.H., Eaton J., et al. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003, 1:6-11.
95. Mizuguchi H., Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002, 1-2:69-77.
96. Bergelson J.M., Cunningham J.A., Droguett G., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 5304:1320-1323.
97. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997, 7:3352-3356.
98. Mizuguchi H., Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004, 11:1034-1044.
99. Rauen K.A., Sudilovsky D., Le J.L., et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002, 13:3812-3818.
100. Campos S.K., Barry M.A. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007, 3:189-204.
101. Dmitriev I., Krasnykh V., Miller C.R., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 12:9706-9713.
102. Wickham T.J., Tzeng E., Shears L.L., et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997, 11:8221-8229.
103. Crompton J., Toogood C.I., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 1994, 133-139.
104. Dmitriev I.P., Kashentseva E.A., Curiel D.T. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002, 14:6893-6899.
105. Wickham T.J., Segal D.M., Roelvink P.W., et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996, 10:6831-6838.
106. Goldman C.K., Rogers B.E., Douglas J.T., et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997, 8:1447-1451.
107. Miller C.R., Buchsbaum D.J., Reynolds P.N., et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998, 24:5738-5748.
108. Alemany R., Suzuki K., Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000, (Pt 11):2605-2609.
109. Croyle M.A., Chirmule N., Zhang Y., Wilson J.M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002, 15:1887-1900.
110. Mok H., Palmer D.J., Ng P., Barry M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005, 1:66-79.
111. Lanciotti J., Song A., Doukas J., et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003, 1:99-107.
112. Fisher K.D., Stallwood Y., Green N.K., et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001, 5:341-348.
113. Goossens P.H., Havenga M.J., Pieterman E., et al. Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis Rheum 2001, 3:570-577.
114. Shayakhmetov D.M., Papayannopoulou T., Stamatoyannopoulos G., Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000, 6:2567-2583.
115. Roelvink P.W., Mi Lee G., Einfeld D.A., Kovesdi I., Wickham T.J. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999, 5444:1568-1571.
116. Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003, 11:1408-1412.
117. Segerman A., Atkinson J.P., Marttila M., et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003, 17:9183-9191.
118. Short J.J., Pereboev A.V., Kawakami Y., et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004, 2:349-359.
119. Sirena D., Lilienfeld B., Eisenhut M., et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004, 9:4454-4462.
120. Tuve S., Wang H., Ware C., et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006, 24:12109-12120.
121. Liu L., Kodibagkar V.D., Yu J.X., Mason R.P. 19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl beta-d-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse. Faseb J 2007, 9:2014-2019.
122. Gade T.P., Koutcher J.A., Spees W.M., et al. Imaging transgene activity in vivo. Cancer Res 2008, 8:2878-2884.
123. Briat A., Vassaux G. Preclinical applications of imaging for cancer gene therapy. Expert Rev Mol Med 2006, 16:1-19.
124. Gambhir S.S., Bauer E., Black M.E., et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000, 6:2785-2790.
125. Kang J.H., Chung J.K. Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008, 164S-179S.
126. Tjuvajev J.G., Finn R., Watanabe K., et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996, 18:4087-4095.
127. Herschman H.R. Noninvasive imaging of reporter gene expression in living subjects. Adv Cancer Res 2004, 29-80.
128. MacLaren D.C., Gambhir S.S., Satyamurthy N., et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999, 5:785-791.
129. Kummer C., Winkeler A., Dittmar C., et al. Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector. Mol Imaging 2007, 3:181-192.
130. Levy O., De la Vieja A., Ginter C.S., et al. N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model. J Biol Chem 1998, 35:22657-22663.
131. Ajjan R.A., Kamaruddin N.A., Crisp M., et al. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol (Oxf) 1998, 4:517-523.
132. Van Sande J., Massart C., Beauwens R., et al. Anion selectivity by the sodium iodide symporter. Endocrinology 2003, 1:247-252.
133. Niu G., Gaut A.W., Ponto L.L., et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med 2004, 3:445-449.
134. Serganova I., Ponomarev V., Blasberg R. Human reporter genes: potential use in clinical studies. Nucl Med Biol 2007, 7:791-807.
135. Barton K.N., Stricker H., Brown S.L., et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008, 10:1761-1769.
136. Gene Therapy Clinical Trials Worldwide. J Gene Med. Updated June 2010; http://www.abedia.com/wiley/vectors.php.